The applications MaxQ AI has developed will help empower physicians to provide “smarter care” with artificial intelligence-based clinical insights, resulting in potential diagnostic improvements, which may lead to better patient outcomes and lower healthcare costs. When minutes matter for patients in acute care, ACCIPIO and the skilled care provider are better together.
In seconds, MaxQ AI applications are being designed to seamlessly prioritize, triage, rule out, annotate, quantify, and notify in the acute care setting. Seamlessly assisting the physicians in making rapid clinical diagnosis and next-step decisions for the patient, where every minute counts.
Interview with Dr. Navdeep Sangha, who is a Neurologist with Kaiser Permanente Los Angeles Medical Center. He is the Co-Assistant Chief of Neurology and the Director of the Kaiser Permanente Southern California TeleStroke Program. During the interview, Dr. Sangha shares his insight into how emerging technology such as AI-powered diagnostic solutions are poised to augment acute care providers in the detection of intracranial hemorrhage (ICH). He also shares a number of case studies and highlights how MaxQ AI’s Accipio Clinical Suite has shown the potential to enhance the identification and prioritization of patients suffering from stroke, head trauma, and other life-threatening conditions.
Provides automatic, rapid, highly accurate triage for suspected ICH presence or high NPV absence.
Provides automatic, rapid, highly accurate identification and prioritization of suspected ICH.
Provides automatic, rapid, highly accurate slice-level annotation & prioritization of suspected ICH.
Provides automatic, rapid, highly accurate lesion-level annotation of suspected ICH.
Accipio Ix™: FDA 510(k) Cleared, CE Marked, TGA Approved, IMOH Approved
Accipio Ax™: CE Marked, TGA Approved; FDA 510(k) pending, Not Available for Sale
Accipio Ax Plus™: Investigational Use Only*, Not Available for Sale
Accipio Ax Pro™: Investigational Use Only*, Not Available for Sale
*CAUTION- Investigational Device, Limited by Federal Law to Investigational Use
Accipio Dxg™: CE Marked, FDA 510(k) pending. Not Available for Sale
Accipio Dx™: Investigational Use Only*, Not Available for Sale
MaxQ AI’s new addition to the Accipio Clinical Suite, Accipio Ax, provides automatic, rapid, highly accurate slice-level annotation & prioritization of suspected ICH in CT non-contrast imaging. With Accipio Ax physicians in the acute care setting will be able to quickly and easily interpret CT imaging and determine the presence of a suspected ICH. Along with Accipio Ix, which identifies and prioritizes suspected ICH cases, radiology teams will be able to provide a comprehensive patient-level assessment that will deliver insights across the diagnosis, prognosis, and therapeutic pathways.
We will improve potential diagnostic quality, confidence, speed, prioritization, and escalation to experts, extending the reach of department specialists.
This enables the possibility of better care in all market segments by bringing rapid clinical confidence to the reader while reducing variability across a care network.
The sheer volume of case-load, image counts, and decreasing physician availability demands a real solution to the burn-out of these front-line care providers.
With many community facilities having only emergency department support, along with no radiologist to read on nights and weekends, and a lack of sub-specialty neuroradiologists to escalate cases, there is often a lack of confidence of treating locally.
In this setting, the lack of confidence in identifying ICH can lead to unwarranted institutional transfer, withholding life-saving stroke care, and delayed action. This can have significant consequences for the patient, physician, and facility.
ACCIPIO provides projected expertise allowing the local facility, which makes the majority of care decisions, to determine the next, best treatment decision on treating there and now, or escalating further to additional resources.
In larger facilities, resources and escalation are not the primary issues. Effective use of these resources and a high-volume of patients are the areas of greatest need.
Having multiple head CT cases stacked in the queue, with no timely prioritization or triage for ICH, is common.
Key resources being used for “stoke mimics”, sent from the network community hospital, divert attention away from those in the greatest need. Over-escalating cases to neuroradiologists diverts attention from the patients that need it most. Mobile Stroke Units (MSU) can transmit early imaging data that helps guide patient routing and preparation of on-arrival resources.
We will provide enhanced escalation and intervention confidence, including mobilization of neurosurgery, thrombolysis, and thrombectomy resources for the right care readied faster.
The recipient of the Mobile Stroke Unit or Life-Flight unit should provide the needed information before they arrive to determine which is the best care facility.
Every patient deflected from stroke to wellness is a net benefit to the bottom line. On average, $150,000 per year in costs is required for stroke support/rehab of a patient*.
Payor/Providers are typically comprised of major metro centers with an academic “hub” and large, networked community facilities.
Compounded with the reality that many community facilities have only emergency department support, with no radiologist to read, or sub-specialty neuroradiologist to escalate the case for assistance – there is a large unmet need that can benefit from the “better together” result of ACCIPIO and the physician.
MaxQ AI is at the forefront of transforming healthcare by empowering physicians to provide “smarter care” through intelligent imaging with actionable insights. We are committed to harnessing the power of artificial intelligence (AI) to raise the level of acute care in hospitals all around the world. We strive to deliver expert results to the physicians that save lives, improve care quality, and lower healthcare costs.